PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
The plan is to advance innovative therapies to drug-resistant cancers
The company enters into collaborations with leading next-generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
Vacuum-Assisted Breast Biopsy (VABB) is an innovative and more effective alternative to the traditional method where benign lumps are removed surgically, leaving scars and causing distress
Subscribe To Our Newsletter & Stay Updated
